Methicillin-resistant staphylococcus aureus: An evolving pathogen

Clinical Infectious Diseases

Volumn 58, Issue SUPPL. 1, 2014, Pages

  Stryjewski, Martin E ^a   Corey, G Ralph ^b,c  

^a CEMIC   (Argentina)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; DAPTOMYCIN; GLYCOPEPTIDE; LINEZOLID; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; COMMUNICABLE DISEASE; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BIOLOGICAL EVOLUTION; DRUG RESISTANCE, BACTERIAL; GENE TRANSFER, HORIZONTAL; GLYCOPEPTIDES; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; POINT MUTATION; STAPHYLOCOCCAL INFECTIONS;

EID: 84892591337     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit613     Document Type: Article

References (117)

1. Kloos WE. Taxonomy and systematic of staphylococci indigenous to humans. In: Crossley KB, Archer GL, eds. The staphylococci in human disease. New York City: Churchill Livingstone, 1997:113-37
2. Exodus 9:8-12 (ESV).
3. Wilson LG. The early recognition of streptococci as causes of disease. Med Hist 1987; 31:403-14
4. Rosenbach FJ. Microorganisms in the wound infections diseases of man.Wiesbaden, Germany: J.F. Bergmann, 1884:18
5. Rammelkamp M. Resistances of Staphylococcus aureus to the action of penicillin. Proc Soc Exp Biol Med 1942; 51:386-9
6. Bondi A Jr, Dietz CC. Penicillin resistant staphylococci. Proc Soc Exp Biol Med 1945; 60:55-8
7. Finland M. Emergence of antibiotic-resistant bacteria. N Engl J Med 1955; 253: 909-22; contd
8. Barber M, Rozwadowska-Dowzenko M. Infection by penicillinresistant staphylococci. Lancet 1948; 2:641-4
9. Brumfitt W, Hamilton-Miller J. Methicillin-resistant Staphylococcus aureus. N Engl J Med 1989; 320:1188-96
10. Jessen O, Rosendal K, Bulow P, Faber V, Eriksen KR. Changing staphylococci and staphylococcal infections. A ten-year study of bacteria and cases of bacteremia. N Engl J Med 1969; 281:627-35
11. Jevons MP. "Celbenin"-resistant staphylococci [letter]. Br Med J 1961; 1:124-5
12. Hartman B, Tomasz A. Altered penicillin-binding proteins in methicillin-resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother 1981; 19:726-35
13. Katayama Y, Ito T, Hiramatsu K. A new class of genetic element, Staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2000; 44:1549-55
14. Classification of staphylococcal cassette chromosome mec (SCCmec): Guidelines for reporting novel SCCmec elements. Antimicrob Agents Chemother 2009; 53:4961-67
15. International Working Group on the Staphylococcal Cassette Chromosome Elements. Currently identified SCCmec types in S. aureus strains. Available at: http://www.sccmec.org/Pages/SCC TypesEN. html. Accessed 13 November 2012
16. Wu S, Piscitelli C, de Lencastre H, Tomasz A. Tracking the evolutionary origin of the methicillin resistance gene: Cloning and sequencing of a homologue of mecA from a methicillin susceptible strain of Staphylococcus sciuri. Microb Drug Resist 1996; 2:435-41
17. Wielders CL, Vriens MR, Brisse S, et al. In-vivo transfer of mecA DNA to Staphylococcus aureus [corrected]. Lancet 2001; 357: 1674-5
18. Enright MC, Robinson DA, Randle G, Feil EJ, Grundmann H, Spratt BG. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci U S A 2002; 99:7687-92
19. Musser JM, Kapur V. Clonal analysis of methicillin-resistant Staphylococcus aureus strains from intercontinental sources: Association of the mec gene with divergent phylogenetic lineages implies dissemination by horizontal transfer and recombination. J Clin Microbiol 1992; 30:2058-63
20. Day NP, Moore CE, Enright MC, et al. Retraction. Science 2002; 295:971
21. Fowler VG Jr, Nelson CL, McIntyre LM, et al. Potential associations between hematogenous complications and bacterial genotype in Staphylococcus aureus infection. J Infect Dis 2007; 196:738-47
22. Gill SR, McIntyre LM, Nelson CL, et al. Potential associations between severity of infection and the presence of virulence-associated genes in clinical strains of Staphylococcus aureus. PLoS One 2011; 6: E18673
23. Peacock SJ, Moore CE, Justice A, et al. Virulent combinations of adhesin and toxin genes in natural populations of Staphylococcus aureus. Infect Immun 2002; 70:4987-96
24. Benner EJ, Kayser FH. Growing clinical significance of methicillinresistant Staphylococcus aureus. Lancet 1968; 2:741-4
25. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006; 368:874-85
26. Kayser FH. Methicillin-resistant staphylococci 1965-75. Lancet 1975; 2:650-53
27. Blackwell CC, Feingold DS. Frequency and some properties of clinical isolates of methicillin-resistant Staphylococcus aureus. Am J Clin Pathol 1975; 64:372-7
28. Cafferkey MT, Hone R, Coleman D, et al. Methicillin-resistant Staphylococcus aureus in Dublin 1971-84. Lancet 1985; 2:705-8
29. Keane CT, Cafferkey MT. Re-emergence of methicillin-resistant Staphylococcus aureus causing severe infection. J Infect 1984; 9:6-16
30. Pavillard R, Harvey K, Douglas D, et al. Epidemic of hospital-acquired infection due to methicillin-resistant Staphylococcus aureus in major Victorian hospitals. Med J Aust 1982; 1:451-4
31. Turnidge J, Lawson P, Munro R, Benn R. A national survey of antimicrobial resistance in Staphylococcus aureus in Australian teaching hospitals. Med J Aust 1989; 150:65, 69-72
32. Wenzel RP, Nettleman MD, Jones RN, Pfaller MA. Methicillinresistant Staphylococcus aureus: Implications for the 1990s and effective control measures. Am J Med 1991; 91:221S-7S.
33. Mackintosh CA, Marples RR, Kerr GE, Bannister BA. Surveillance of methicillin-resistant Staphylococcus aureus in England and Wales, 1986-1990. J Hosp Infect 1991; 18:279-92
34. Cookson BD, Phillips I. Epidemic methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1988; 21 (Suppl C):57-65
35. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-85
36. Guzman-Blanco M, Mejia C, Isturiz R, et al. Epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in Latin America. Int J Antimicrob Agents 2009; 34:304-8
37. Bell JM, Turnidge JD, SENTRY APAC. High prevalence of oxacillinresistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa: Results from SENTRY antimicrobial surveillance program, 1998-1999. Antimicrob Agents Chemother 2002; 46:879-81
38. de Lencastre H, Oliveira D, Tomasz A. Antibiotic resistant Staphylococcus aureus: A paradigm of adaptive power. Curr Opin Microbiol 2007; 10:428-35
39. Oliveira DC, Tomasz A, de Lencastre H. Secrets of success of a human pathogen: Molecular evolution of pandemic clones of meticillinresistant Staphylococcus aureus. Lancet Infect Dis 2002; 2:180-9
40. Grundmann H, Aanensen DM, van den Wijngaard CC, Spratt BG, Harmsen D, Friedrich AW. Geographic distribution of Staphylococcus aureus causing invasive infections in Europe: A molecular-epidemiological analysis. PLoS Med 2010; 7:e1000215
41. Burton DC, Edwards JR, Horan TC, Jernigan JA, Fridkin SK. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA 2009; 301:727-36
42. Landrum ML, Neumann C, Cook C, et al. Epidemiology of Staphylococcus aureus blood and skin and soft tissue infections in the US military health system, 2005-2010. JAMA 2012; 308:50-9
43. Centers for Disease Control and Prevention (CDC). Vital signs: Central line-associated blood stream infections - United States, 2001, 2008, and 2009. MMWR Morb Mortal Wkly Rep 2011; 60:243-8
44. Office for National Statistics. Deaths involving MRSA: England and Wales, 2006 to 2010. 23 August 2011. Available at: Http://www.ons. gov.uk/ons/rel/subnational-health2/deaths-involving-mrsa/2006-to-2010/ statistical-bulletin.html. Accessed 13 November 2012
45. Mohr JF, Murray BE. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44:1536-42
46. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44:1208-15
47. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in nonvancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007; 60:788-94
48. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006; 44:3883-6
49. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40:135-6
50. Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, Labischinski HHiramatsu K. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother 1998; 42:199-209
51. Hanaki H, Labischinski H, Inaba Y, Kondo N, Murakami H, Hiramatsu K. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50
52. Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003; 36:429-39
53. Boyle-Vavra S, Berke SK, Lee JC, Daum RS. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother 2000; 44:272-7
54. de Lassence A, Hidri N, Timsit JF, et al. Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit. Clin Infect Dis 2006; 42:170-8
55. Saravolatz LD, Pawlak J, Johnson LB. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates. Clin Infect Dis 2012; 55:582-6
56. Centers for Disease Control and Prevention (CDC). Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:565-7
57. Weigel LM, Clewell DB, Gill SR, et al. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 2003; 302:1569-71
58. Network on Antimicrobial Resistance in S. aureus (NARSA). Glycopeptide resistant staphylococci. Available at: Http://www.narsa.net/ control/member/search?repositoryId=99. Accessed 13 November 2012
59. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350:1670-3
60. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38:448-51
61. Tenover FC. The quest to identify heterogeneously resistant vancomycin-intermediate Staphylococcus aureus strains. Int J Antimicrob Agents 2010; 36:303-6
62. van Hal SJ, Wehrhahn MC, Barbagiannakos T, et al. Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates. J Clin Microbiol 2011; 49:1489-94
63. Richter SS, Satola SW, Crispell EK, et al. Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States. J Clin Microbiol 2011; 49:4203-7
64. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008; 46:2950-4
65. Bae IG, Federspiel JJ, Miró JM, et al. Heterogeneous vancomycinintermediate susceptibility phenotype in bloodstream methicillinresistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: Prevalence, genotype, and clinical significance. J Infect Dis 2009; 200:1355-66
66. Haque NZ, Zuniga LC, Peyrani P, et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest 2010; 138:1356-62
67. Parer S, Lotthe A, Chardon P, Poncet R, Jean-Pierre H, Jumas-Bilak E. An outbreak of heterogeneous glycopeptide-intermediate Staphylococcus aureus related to a device source in an intensive care unit. Infect Control Hosp Epidemiol 2012; 33:167-74
68. Lowy FD. Antimicrobial resistance: The example of Staphylococcus aureus. J Clin Invest 2003; 111:1265-73
69. Malachowa N, DeLeo FR. Mobile genetic elements of Staphylococcus aureus. Cell Mol Life Sci 2010; 67:3057-71
70. Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother 2013; 68:4-11
71. Mishra NN, Yang SJ, Sawa A, et al. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53:2312-8
72. Mehta S, Cuirolo AX, Plata KB, et al. VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2012; 56: 92-102
73. Sánchez García M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010; 303:2260-4
74. Patel JB, Jevitt LA, Hageman J, McDonald LC, Tenover FC. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 2006; 42:1652-3
75. Levine DP, Cushing RD, Jui J, Brown WJ. Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center. Ann Intern Med 1982; 97:330-8
76. Udo EE, Pearman JW, Grubb WB. Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus inWestern Australia. J Hosp Infect 1993; 25:97-108
77. Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillinresistant Staphylococcus aureus infections in France: Emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002; 35:819-24
78. Ma XX, Galiana A, Pedreira W, et al. Community-acquired methicillin-resistant Staphylococcus aureus, Uruguay. Emerg Infect Dis 2005; 11:973-6
79. Wang CC, Lo WT, Chu ML, Siu LK. Epidemiological typing of community-acquired methicillin-resistant Staphylococcus aureus isolates from children in Taiwan. Clin Infect Dis 2004; 39:481-7
80. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46 (Suppl 5):S368-77
81. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359:753-9
82. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillinresistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006; 144: 309-17
83. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666-74
84. Robert J, Tristan A, Cavalié L, et al. Panton-Valentine leukocidinpositive and toxic shock syndrome toxin 1-positive methicillinresistant Staphylococcus aureus: A French multicenter prospective study in 2008. Antimicrob Agents Chemother 2011; 55:1734-9
85. Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006; 42:647-56
86. Davis SL, Rybak MJ, Amjad M, Kaatz GW, McKinnon PS. Characteristics of patients with healthcare-associated infection due to SCCmec type IV methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 2006; 27:1025-31
87. Diep BA, Chambers HF, Graber CJ, et al. Emergence of multidrugresistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med 2008; 148:249-57
88. Hageman JC, Patel J, Franklin P, et al. Occurrence of a USA300 vancomycin-intermediate Staphylococcus aureus. Diagn Microbiol Infect Dis 2008; 62:440-2
89. Murthy MH, Olson ME, Wickert RW, Fey PD, Jalali Z. Daptomycin non-susceptible meticillin-resistant Staphylococcus aureus USA 300isolate. J Med Microbiol 2008; 57:1036-8
90. Chua K, Laurent F, Coombs G, Grayson ML, Howden BP. Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy. Clin Infect Dis 2011; 52:99-114
91. Deleo FR, Otto M, Kreiswirth BN, Chambers HF. Community-associated meticillin-resistant Staphylococcus aureus. Lancet 2010; 375:1557-68
92. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AWCarmeli Y. Comparison of mortality associated with methicillinresistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003; 36:53-9
93. Whitby M, McLaws ML, Berry G. Risk of death from methicillinresistant Staphylococcus aureus bacteraemia: A meta-analysis. Med J Aust 2001; 175:264-7
94. Zahar JR, Clec'h C, Tafflet M, et al. Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia? Clin Infect Dis 2005; 41:1224-31
95. Combes A, Luyt CE, Fagon JY, et al. Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia. Am J Respir Crit Care Med 2004; 170:786-92
96. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillinresistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193-200
97. Hidayat LK, Hsu DI, Quist R, Shriner KA,Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity. Arch Intern Med 2006; 166:2138-44
98. Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011; 204:340-7
99. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: A systematic review and meta-analysis. Clin Infect Dis 2012; 54:755-71
100. van Hal SJ, Paterson DL. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011; 55:405-10
101. van Hal SJ, Jones M, Gosbell IB, Paterson DL. Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillinresistant Staphylococcus aureus blood stream infections. PloS One 2011; 6:e21217
102. Dunman PM, Murphy E, Haney S, et al. Transcription profiling-based identification of Staphylococcus aureus genes regulated by the agr and/ or sarA loci. J Bacteriol 2001; 183:7341-53
103. Moise PA, Forrest A, Bayer AS, Xiong YQ, Yeaman MR, Sakoulas G. Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: Role of platelet microbicidal protein killing and agr genotypes. J Infect Dis 2010; 201:233-40
104. Fowler VG Jr, Sakoulas G, McIntyre LM, et al. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis 2004; 190:1140-9
105. Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007; 51:2582-6
106. Schweizer ML, Furuno JP, Sakoulas G, et al. Increased mortality with accessory gene regulator (agr) dysfunction in Staphylococcus aureus among bacteremic patients. Antimicrob Agents Chemother 2011; 55:1082-7
107. Lipinska U, Hermans K, Meulemans L, et al. Panton-Valentine leukocidin does play a role in the early stage of Staphylococcus aureus skin infections: A rabbit model. PloS One 2011; 6:e22864
108. Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29:1128-32
109. Bae IG, Tonthat GT, Stryjewski ME, et al. Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: Results of a multinational trial. J Clin Microbiol 2009; 47:3952-7
110. Lalani T, Federspiel JJ, Boucher HW, et al. Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients. J Clin Microbiol 2008; 46:2890-6
111. Peyrani P, Allen M, Wiemken TL, et al. Severity of disease and clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus strains not influenced by the presence of the Panton-Valentine leukocidin gene. Clin Infect Dis 2011; 53:766-71
112. Sharma-Kuinkel BK, Ahn SH, Rude TH, et al. Presence of genes encoding Panton-Valentine leukocidin is not the primary determinant of outcome in patients with hospital-acquired pneumonia due to Staphylococcus aureus. J Clin Microbiol 2012; 50:848-56
113. Skinner D, Keefer CS. Significance of bacteremia caused by Staphylococcus aureus. Arch Intern Med 1941; 68:851-75
114. de Kraker ME, Wolkewitz M, Davey PG, et al. Clinical impact of antimicrobial resistance in European hospitals: Excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother 2011; 55:1598-605
115. Kuehnert MJ, Hill HA, Kupronis BA, Tokars JI, Solomon SL, Jernigan DB. Methicillin-resistant-Staphylococcus aureus hospitalizations, United States. Emerg Infect Dis 2005; 11:868-72
116. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillinresistant Staphylococcus aureus infections in the United States. JAMA 2007; 298:1763-71
117. Hoyert DL, Xu JQ. Deaths: Preliminary data for 2011. Natl Vital Stat Rep 2012; 61:1-52